Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4618980 | 0.85 | RAB9A (0.51) | RAB9APRMT5WDR77KDM4EMAPT | |
| SCHEMBL4617021 | 0.82 | MEN1 (0.59) | RAB9APRMT5WDR77KDM4EMAPT | |
| SCHEMBL29451559 | 0.81 | PRMT5 (0.51) | RAB9APRMT5WDR77KDM4EMAPT | |
| SCHEMBL4618304 | 0.81 | SFRP1 (0.71) | RAB9APRMT5WDR77KDM4EMAPT | |
| SCHEMBL6102779 | 0.80 | SFRP1 (0.54) | RAB9APRMT5WDR77KDM4EMAPT | |
| SCHEMBL29452025 | 0.78 | PKM (0.51) | RAB9APRMT5WDR77KDM4EMAPT | |
| SCHEMBL4616855 | 0.78 | RAB9A (0.67) | RAB9AKDM4EMAPTHTTATM | |
| SCHEMBL6104417 | 0.76 | SFRP1 (0.58) | RAB9APRMT5WDR77KDM4EMAPT | |
| SCHEMBL4616910 | 0.76 | SFRP1 (0.64) | RAB9APRMT5WDR77KDM4EMAPT | |
| SCHEMBL4616670 | 0.76 | MEN1 (0.56) | RAB9APRMT5WDR77KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | RAB9A 1163/4885PRMT5 1341/4885WDR77 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.